MedPiper Technologies, Inc

medpiper.com →

-67%

est. 2Y upside i

HealthcareSeries A

Salesforce for health data

Rank

#1156

Sector

HealthTech, SaaS

Est. Liquidity

~5Y

Data Quality

Data: Medium

MedPiper Technologies presents a moderate upside opportunity with higher risk, primarily due to its early stage and the significant competitive landscape.

Last updated: March 10, 2026

Bull (25%)+350%

MedPiper successfully expands its enterprise customer base by leveraging its full-stack data platform and AI capabilities, securing major contracts with insurers and pharmaceutical companies. This drives revenue to $10M+ within two years, justifying a valuation of $54M at a premium multiple due to its proprietary data and strong market adoption.

Base (40%)+50%

MedPiper continues to grow steadily within its niche, acquiring new customers and expanding its platform features. While facing competition, it maintains its market position, reaching approximately $2M in revenue and an $18M valuation, reflecting solid execution but limited breakout growth in the near term.

Bear (35%)-80%

Intense competition from well-funded incumbents like Innovaccer and IQVIA, coupled with high regulatory hurdles and slower-than-expected customer acquisition, stifles MedPiper's growth. Revenue stagnates, leading to a down round or acquisition at a significantly reduced valuation of $2.4M, severely impacting common stock value.

Est. time to liquidity~5.0 years

Preference Stack Risk

high

Investors hold $3M in liquidation preferences, representing 25% of the estimated $12M current valuation.

Dilution Risk

high

As an early-stage company (Series A), significant future dilution is likely as the company will require additional funding rounds to scale.

Secondary Liquidity

none

There is no active secondary market or tender offer for shares in this early-stage, privately held company.

Questions to Ask at the Interview

Strategic questions based on MedPiper Technologies, Inc's data — designed to show you've done your homework.

  • 1

    “How does MedPiper plan to differentiate its full-stack data platform and proprietary data offerings to effectively compete with the established market presence and resources of incumbents like Innovaccer and IQVIA?”

  • 2

    “With current annual revenue around $673,000, what are the key milestones and growth strategies MedPiper aims to achieve over the next 12-24 months to significantly scale revenue and demonstrate a clear path to profitability?”

  • 3

    “Given the 'Early Stage VC' funding and the current market conditions, what is the company's anticipated timeline and strategy for future funding rounds or a potential liquidity event for employees?”

Community

Valuation Sentiment

Our model estimates -67% upside. What do you think?

Anonymous. Do not share material non-public information.

Community Discussion

Comments are reviewed before they appear publicly.

0/2000

Loading comments...

Disclaimer: This analysis is AI-generated and does not constitute financial or career advice. Always conduct your own due diligence.